Additionally, asparaginase, used in the treatment of acute lymphoblastic leukemia, has been shown to inhibit the lectin pathway of the complement system by reducing its effect on levels of mannan-bound MBL/MASP-1 and MBL/MASP-2 complexes15. Here, MBL2 is linked to acute lymphoblastic leukemia.